COMMUNIQUÉS West-GlobeNewswire

Verano Hosting Grand Opening Celebration of MÜV Bradfordville on Friday, July 17th, Elevating the Company’s Retail Footprint to 86 Florida Dispensaries and 163 Locations Nationwide
14/07/2026
MÜV Bradfordville is located in the Tallahassee area on a commercial stretch of Thomasville Road that has an average daily traffic count of 13,305 vehicles 1 MÜV Bradfordville is the Company’s second location in Leon [...]
The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
14/07/2026
Conexeu Sciences is aiming CXU™ at the largest unclaimed frontier in injectable aesthetics: restoring body fullness at a scale today's fillers were never built to reach. The move builds on the company's completed 12- [...]
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
14/07/2026
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will [...]
PetVivo Holdings Announces Publication of Peer-Reviewed Clinical Study Evaluating Spryng® in Veterinary Record
14/07/2026
Peer-Reviewed Study Demonstrates Feasibility and Statistically Significant Improvements in Subjective Clinical Outcomes in Dogs with Stifle Osteoarthritis and Suspected Cranial Cruciate Disease Minneapolis, MN, July 14 [...]
SRX Global Reports Paper-Traded EMJX Return of ~25% Since February 11, 2026
14/07/2026
EMJX Shifted from “Stress” to “Mixed” for Bitcoin Company Files Updated Investor Presentation Outlining Performance and Strategy Management to Host Fireside Chat Today at 10:30am ET NORTH PALM BEACH, Fla., July 14, 2026 [...]
Supernus Celebrates Five-Year Anniversary of Qelbree® FDA Approval, Continuing to Deliver on Real-World Experience in ADHD
14/07/2026
Qelbree remains the first novel, non-stimulant ADHD medication approved in over a decade and is the only ADHD treatment with serotonin (5-HT 2C ) pharmacodynamics approved in its FDA product labeling. Qelbree has [...]
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
14/07/2026
Acquisition adds seven commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term [...]
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
14/07/2026
$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offering IRVINE, Calif., July 14, 2026 ( [...]
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
14/07/2026
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients – – Updated data expected to support darlifarnib’s potential [...]
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus
14/07/2026
Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver Disease with No [...]
Dandy Unveils Polychromatic Shade™ to End the Trade-Off Between Dental Aesthetics and Affordability
14/07/2026
Breakthrough innovation delivers natural-looking zirconia crowns and bridges at a fraction of the cost of hand-painted porcelain NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Dandy , the fully digital dental lab, today [...]
Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access
14/07/2026
- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple roles including Executive Vice President and Chief Medical Officer for Fresenius Medical Care North America - - Dr. [...]
Genopore appoints Rey Mali as Chief Executive Officer to accelerate growth of the pioneering protein identification company
14/07/2026
SAN FRANCISCO and YAVNE, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Genopore, the next-generation proteomics company developing the first semiconductor based optical nanopore technology platform with AI/ML analysis for [...]
Nucleome Therapeutics strengthens global IP portfolio with US patent for core MCC Technology
14/07/2026
Nucleome’s advance in precision and scale of 3D genomics has solved the fundamental challenge of discovering molecular drivers of disease from human genetics OXFORD, United Kingdom, July 14, 2026 (GLOBE NEWSWIRE) -- [...]
Transactions in connection with share buy-back program
14/07/2026
Company announcement no. 25 - 26 14 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Hummingbird Bioscience Wins APAC Trailblazer Award at 2026 Nebius AI Discovery Awards
14/07/2026
From 647 applications worldwide, Hummingbird Bioscience was selected by an independent judging panel as a winner at the AI Discovery Awards hosted by Nebius The awards program spotlights companies leveraging AI to [...]
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody
14/07/2026
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an upfront payment, and is [...]
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
14/07/2026
Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and [...]
ViCentra Appoints Ian Wells as Chief Financial Officer and Adds Medtech Veteran Tom West to its Board
14/07/2026
Ian Wells, former Global Chief Financial Officer of HOYA Vision Care, appointed CFO, bringing multi-billion-dollar P&L leadership and capital-markets discipline Tom West, who led Intersect ENT to its $1.1 billion [...]

Pages